Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Effect of lysozyme on exacerbation of chronic obstructive pulmonary disease : a randomised placebo-controlled study

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080222006

Enrollment

400

Registered

2013-01-24

Start date

2013-01-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

investigational material(s) Generic name etc : Lysozyme hydrochloride (LYS) INN of investigational material : Therapeutic category code : 395 Enzyme preparations Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients were eligible for inclusion in the study if they had a smoking history, a diagnosis of COPD, %FEV1< 80% and a ratio of FEV1 to forced vital capacity(FVC) of < 70%, and a documented history of at least one exacerbation leading to any treatment within the previous year.

Exclusion criteria

Exclusion criteria: Patients with egg allergy Patients with domiciliary oxygen therapy Patients with pneumonia or pulmonary tuberculosis Patients with severe cardiovascular disorder, severe kidney disorder, severe hepatic disorder, severe hematological disorder Patients with cancer

Design outcomes

Primary

Measure	Time frame
Efficacy Exacerbation of chronic obstructive pulmonary disease	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026